Directive 75/318/EEC

Directive 75/318/EEC of 20 May 1975 on the approximation of the laws of Member States relating to analytical, pharmaco-toxicological and clinical standards and protocols in respect of the testing of proprietary medicinal products. This directive of the European Union sought to bring the benefits of innovative pharmaceuticals to patients across Europe by introducing the mutual recognition, by Member States, of their respective national marketing authorisations.

The Directive states that Member States shall take all appropriate measures to ensure that the applications for marketing authorization, are submitted by the applicants in accordance with the guidelines of the Directive.

See also

References

This article is issued from Wikipedia - version of the Tuesday, January 29, 2013. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.